Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-02-27
DOI
10.3389/fimmu.2018.00377
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin 32, inflammation and cancer
- (2017) Jin Tae Hong et al. PHARMACOLOGY & THERAPEUTICS
- Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells
- (2016) Andy Göbel et al. CANCER LETTERS
- Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells
- (2016) Jaydeep Bhat et al. Oncotarget
- T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
- (2016) Zhan Wang et al. Frontiers in Immunology
- In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors
- (2015) Jacqueline E. Reilly et al. BIOCHEMICAL PHARMACOLOGY
- Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner
- (2015) L. Fernández et al. CANCER LETTERS
- Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells
- (2015) S. Arkko et al. CANCER LETTERS
- Type I IFNs and IL-18 Regulate the Antiviral Response of Primary Human γδ T Cells against Dendritic Cells Infected with Dengue Virus
- (2015) Chen-Yu Tsai et al. JOURNAL OF IMMUNOLOGY
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study
- (2015) H-Y Li et al. Cell Death & Disease
- γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?
- (2015) Jaydeep Bhat et al. OncoImmunology
- Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma
- (2015) Binghao Li et al. Oncotarget
- Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ
- (2014) Jens HW Pahl et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma
- (2013) Hiroki Goto et al. CANCER LETTERS
- Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway
- (2013) Zhiqiang Zhao et al. CANCER LETTERS
- Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid
- (2013) Atif S. M. Idrees et al. CANCER SCIENCE
- Repeated Systemic Administrations of Both Aminobisphosphonates and Human V 9V 2 T Cells Efficiently Control Tumor Development In Vivo
- (2013) T. Santolaria et al. JOURNAL OF IMMUNOLOGY
- At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias
- (2013) Håkan Norell et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Zoledronic Acid Produces Antitumor Effects on Mesothelioma Through Apoptosis and S-Phase Arrest in p53-Independent and Ras prenylation-Independent Manners
- (2012) Shinya Okamoto et al. Journal of Thoracic Oncology
- Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
- (2011) J. H. W. Pahl et al. CLINICAL CANCER RESEARCH
- Rapid and Transient Activation of T Cells to IFN- Production, NK Cell-Like Killing, and Antigen Processing during Acute Virus Infection
- (2011) F. N. Toka et al. JOURNAL OF IMMUNOLOGY
- Indirect Stimulation of Human Vγ2Vδ2 T Cells through Alterations in Isoprenoid Metabolism
- (2011) Hong Wang et al. JOURNAL OF IMMUNOLOGY
- Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate
- (2011) Zhaoxu Li et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- Osteosarcoma
- (2010) J. Ritter et al. ANNALS OF ONCOLOGY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma
- (2010) Masanori Kawano et al. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
- Osteosarcoma treatment: state of the art
- (2009) Hang T. Ta et al. CANCER AND METASTASIS REVIEWS
- Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis
- (2009) Xuzhang Lu et al. CANCER SCIENCE
- Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V 9V 2 T Cells
- (2009) J. Li et al. JOURNAL OF IMMUNOLOGY
- Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
- (2009) A Poggi et al. LEUKEMIA
- Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients
- (2008) Stefan S. Bielack et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started